J
John M. Lachin
Researcher at George Washington University
Publications - 363
Citations - 88368
John M. Lachin is an academic researcher from George Washington University. The author has contributed to research in topics: Diabetes mellitus & Type 1 diabetes. The author has an hindex of 93, co-authored 341 publications receiving 80403 citations. Previous affiliations of John M. Lachin include National Institutes of Health & Milken Institute.
Papers
More filters
Journal ArticleDOI
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
Diabetes Control,David M. Nathan,Saul M. Genuth,John M. Lachin,Patricia A. Cleary,O Crofford,Matthew M. Davis,Larry Rand,Carolyn Siebert +8 more
TL;DR: Intensive therapy effectively delays the onset and slows the progression of diabetic retinopathy, nephropathy, and neuropathy in patients with IDDM.
Journal ArticleDOI
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
William C. Knowler,Elizabeth Barrett-Connor,Sarah E. Fowler,Richard F. Hamman,John M. Lachin,Elizabeth A. Walker,David M. Nathan +6 more
TL;DR: In this paper, the authors compared a lifestyle intervention with metformin to prevent or delay the development of Type 2 diabetes in nondiabetic individuals. And they found that the lifestyle intervention was significantly more effective than the medication.
Journal ArticleDOI
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman,Christoph Wanner,John M. Lachin,David Fitchett,Erich Bluhmki,Stefan Hantel,Michaela Mattheus,Theresa Devins,Odd Erik Johansen,Hans-Juergen Woerle,Uli C. Broedl,Silvio E. Inzucchi +11 more
TL;DR: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.
Journal ArticleDOI
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M. Nathan,Patricia A. Cleary,Jye Yu C. Backlund,Saul Genuth,John M. Lachin,Trevor J. Orchard,Philip Raskin,Bernard Zinman +7 more
TL;DR: Intensive diabetes therapy has long-term beneficial effects on the risk of cardiovascular disease in patients with type 1 diabetes, and changes between treatment groups remained significant after adjusting for these factors.
Journal ArticleDOI
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Steven E. Kahn,Steven M. Haffner,Heise Ma,William H. Herman,Rury R. Holman,Nigel P. Jones,Barbara G. Kravitz,John M. Lachin,O'Neill Mc,Bernard Zinman,Giancarlo Viberti +10 more
TL;DR: The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes.